부산광역시내과

2026 대한조혈모세포이식학회 국제학술대회(ICBMT 2026) - 9월 17일(1일차)

Name: 2026 대한조혈모세포이식학회 국제학술대회(ICBMT 2026) - 9월 17일(1일차)
Start: 2026-09-17
End: 2026-09-17
Location: 벡스코

6.0점 일반 6.0

주최: 대한조혈모세포이식학회
일자: 2026-09-17
장소: 벡스코
수강료: 200,000원 구분별

수강료 구분별 상세보기

회원 150,000원, 비회원 200,000원, 기타 80,000원

원문 기준 · 정확한 등록비는 KMA 신청 페이지에서 확인하세요.

평점 구성

총 평점6.0점

필수평점0점

일반평점6.0점

연수평점은 3년 24점·연 8점 상한·필수 2점 요건이 있습니다. 이 행사 들으면 올해 상한까지 몇 점? →

KMA 등록 페이지에서 신청 → 평점 계산기

세부 일정 (60강)

09:00~09:10 [구연발표]Distinct Genetic Architecture and Integrated Risk Stratification in Adult ETP-ALL and Other T-ALL Room A Seonghan Lee(Seoul St. Marys Hospital College of Medicine The Catholic University of Korea)
09:10~09:20 [구연발표]Inotuzumab Ozogamicin as Salvage Therapy Prior to Second Allogeneic Hematopoietic Cell Transplantation Reduces Relapse Without Increasing Non-Relapse Mortality in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Room A Joon Young Hur(Asan Medical Center University of Ulsan College of Medicine)
09:20~09:30 [구연발표]TAL1 Activation Mechanisms Stratify Relapse Risk and Identify a High-Risk Subgroup Unresponsive to HSCT in Pediatric T-ALL Room A Senlin Zhang(Childrens Hospital of Soochow University)
09:30~09:40 [구연발표]Genomic Landscape and Clinical Outcomes of MTAP Rearrangements in Pediatric T-Cell Acute Lymphoblastic Leukemia: A Retrospective Cohort Study Room A Shier Cheng(Childrens Hospital of Soochow University)
09:40~09:50 [구연발표]Successful transplant-sparing management of EBF1::PDGFRB-positive Ph-like acute lymphoblastic leukemia using imatinib and CD19 CAR-T therapy with prolonged TKI maintenance Room A Hina Nakajima(Chiba University Hospital)
09:50~10:00 [구연발표]Clinical Outcomes of Adults with Ph-Positive ALL Treated with Frontline Ponatinib Plus Hyper-CVAD Followed by RTC-Allo-HCT Incorporating ATG/PTCy; Additional Role of Ponatinib Prophylaxis Room A Jong Hyuk Lee(Incheon St. Marys Hospital College of MedicineIncheon St. Mary's Hospital College of Medicine)
09:00~09:10 [구연발표]Multi-Trajectories of Lipid Profiles and Their Association with Clinical Outcomes in AML Patients Undergoing allo-HSCT Room B Hongru Chen(Peking University Peoples Hospital)
09:10~09:20 [구연발표]High Frequency of Extramedullary Relapse in Very Late Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation Room B Jin-Hee Han(Asan Medical Center)
09:20~09:30 [구연발표]Comparable Post-Transplant Outcomes Following Intensive Chemotherapy versus Hypomethylating Agent plus Venetoclax Before First Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Room B Hyunkyung Park(Asan Medical Center University of Ulsan College of Medicine)
09:30~09:40 [구연발표]HCT-CI Failed to Predict Survival Outcomes in Elderly Patients with AML/MDS Undergoing Haploidentical Transplantation Room B Yuqian Sun(Peking University Peoples Hospital)
09:40~09:50 [구연발표]Venetoclax Plus Hypomethylating Agents for Acute Myeloid Leukemia Relapsing After Allogeneic Hematopoietic Cell Transplantation Room B Jiseon Park(Asan Medical Center University of Ulsan College of Medicine)
09:50~10:00 [구연발표]Efficacy and Safety of Venetoclax and Azacitidine Maintenance in Reducing Relapse After Haploidentical HSCT for Pediatric AML: A Retrospective Two-Center Cohort Study Room B He Hongbo(Beijing Childrens Hospital)
09:00~09:10 [구연발표]Discovery of a Novel Quiescence-Associated Marker of Top-Tier Hematopoietic Stem Cells in Umbilical Cord Blood by Transcriptomic Profiling Room C Dong-Yeop Shin(Seoul National University Hospital College of Medicine)
09:10~09:20 [구연발표]Longitudinal Single-Cell Profiling of Bone Marrow Reveals Intercellular Communication Rewiring in Chronic Graft-versus-Host Disease Room C Jong Hyuk Lee(Incheon St. Marys Hospital College of Medicine)
09:20~09:30 [구연발표]Ectopic EBV Infection in T Cells Identifies Reduced Therapeutic Responsiveness and Immune Dysfunction After Allogeneic Hematopoietic Stem Cell Transplantation Room C Zhifan Zhao(Peking University)
09:30~09:40 [구연발표]An Integrated Single-Cell Atlas of Acute Lymphoblastic Leukemia Defines Malignant-Core State Architecture Across Clinical and Molecular Contexts Room C Javad Alizargar(National Taipei University of Nursing)
09:40~09:50 [구연발표]HLA Structural Profiles Identified by Protein Language Models Predict Graft Failure in Haploidentical Transplantation Room C Rui Ma(Peking University Peoples Hospital)
09:50~10:00 [구연발표]Tumor Necrosis Factor is a Growth Factor for Mesenchymal Stromal Progenitor Cells Room C Aleksei Bigildeev(Moscow institute for physics and technology (MIPT))
09:00~09:10 [구연발표]Model-Predicted Antithymocyte Globulin Exposure And Clinical Outcomes After Haploidentical Peripheral Blood Stem Cell Transplantation In Adult Acute Myeloid Leukemia Room D Daehun Kwag(Catholic Hematology Hospital Seoul St. Mary)
09:10~09:20 [구연발표]Older Matched Sibling Donors Remain a Favorable Option in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia: Impact of Donor Age Across Donor Types Room D So Yeon Park(Seoul St. Marys Hospital College of Medicine)
09:20~09:30 [구연발표]Pegylated versus daily G-CSF for peripheral blood stem cell mobilization in allogeneic hematopoietic cell transplantation donors Room D Ryo Sato(Yamagata University)
09:30~09:40 [구연발표]Sequential Haploidentical-Cord Blood Hematopoietic Stem-Cell Transplantation With PT-Cy/Flu in Pediatric Acute Leukemia Room D Zhilin Hu(Shenzhen Children)
09:40~09:50 [구연발표]The Comparison of Bone Marrow plus Peripheral Blood versus Peripheral Blood as Graft Source in Haploidentical Stem Cell Transplantation for Older Patients Room D Wei Zhao(Peking University Peoples Hospital)
09:50~10:00 [구연발표]Successful Multi-Modal Management of Refractory CMV-Associated Hemophagocytic Lymphohistiocytosis and Idiopathic Pneumonia Syndrome Following HLA-Mismatched Bone Marrow Transplantation for Severe Aplastic Anemia Room D Yuichi Kobayashi(Chiba University)
10:00~10:30 휴식 ( )
10:30~11:10 Current Real World Practice to Optimize Outcomes of CAR T Cell Therapy for Pediatric ALL Room A Stephen A. Grupp(Childrens Hospital of Philadelphia)
11:10~11:50 Eliminating GVHD Prophylaxis: A New Era of Sequential CAR-T and Allogeneic HSCT Room A He Huang(The First Affiliated Hospital Zhejiang University School of Medicine)
11:50~12:00 휴식 ( )
12:00~12:40 Optimizing cGVHD Management After Ruxolitinib Failure: The Role of Belumosudil in Clinical Practice Room A Jia Chen(The First Affiliated Hospital of Soochow University)
12:00~12:40 Maintaining Relative Dose Intensity in Elderly DLBCL: Clinical Strategies with Pegfilgrastim Room C Hyunsoo Cho(Seoul National University Hospital)
12:00~12:40 Real World Evidence on the Efficacy and Safety of Iptacopan in PNH Management Room D Silvia Park(College of Medicine The Catholic University of Korea)
12:40~13:00 휴식 ( )
13:00~13:40 Beyond Immunosuppression: Enhancing Tissue Resilience to Mitigate GVHD Room A Pavan Reddy(Dan L. Duncan Comprehensive Cancer Center)
13:40~14:20 Immunologic Mechanisms and Modulation of Chronic Graft-Versus-Host Disease Room A Bruce R. Blazar(University of Minnesota)
14:20~14:30 휴식 ( )
14:30~15:00 Advances in Ex Vivo T Cell Depletion Room A Margaret MacMillan(University of Minnesota)
15:00~15:30 Selective T cell Depletion and Enrichment Room A Marie Bleakley(Fred Hutchinson Cancer Center)
15:30~16:00 Optimizing T-Cell Modulation in Adult ALL Transplantation: ATG, PTCy, and Donor-Specific GVHD Control Room A Jae-Ho Yoon(College of Medicine The Catholic University of Korea)
14:30~15:00 Biomarkers and Immune Fitness Shaping Outcomes of Immune Effector Cell Therapies Room B Rizwan Romee(Dana-Farber Cancer Institute)
15:00~15:30 In Vivo CAR-T Engineering for Lymphoid Malignancies Room B Heng Mei(Union Hospital Tongji Medical College Huazhong University of Science and Technology)
15:30~16:00 Overcoming Resistance in T-cell Malignancies: From Phase 1 Study of CD5-targeted Allogeneic CAR-NK Cells Room B Dok Hyun Yoon(University of Ulsan College of Medicine)
14:30~15:00 Virus-specific T Cells for Adoptive Immunotherapy Room C Susan E. Prockop(Dana-Farber Cancer Institute)
15:00~15:30 Strategies for Determining Treatment Flow of CAR T-Cell Therapy and HSCT in Pediatric ALL Room C Krzysztof Kalwak(Wroclaw Medical University)
15:30~16:00 Clinical Applications of Donor Lymphocyte Infusion in Pediatric Malignancies Room C Hee Young Ju(Sungkyunkwan University School of Medicine)
14:30~15:00 Management of Poor Graft Function in Chilren Room D Eun Sang Yi(Korea University College of Medicine)
15:00~15:30 Donor Lymphocyte Infusion (DLI) in 2026: Indications, Dosing, and GVHD Trade-offs Room D Hyunkyung Park(University of Ulsan College of Medicine)
15:30~16:00 Cellular Support Beyond the Graft: Integrative Strategis after Allogeneic HSCT Room D Koen Van Besien(Case Western Reserve University School of Medicine)
16:00~16:10 휴식 ( )
16:10~16:40 Poster Poster Zone 3F ( )
16:40~16:50 휴식 ( )
16:50~17:15 Germline Traits and Donor Selection for Allo-HCT: on Overview and the Paradigm of DDX41 Room A Carmelo Gurnari(University of Tor Vergata)
17:15~17:40 Which Donor Should We Use in the Absence of a Matched Sibling in Aplastic Anemia? Room A Juan Montoro(La Fe University and Polytechnic Hospital)
17:40~18:05 Clonal Hematopoiesis in Hematopoietic Stem Cell Transplantation Room A Youngil Koh(Seoul National University College of Medicine)
18:05~18:30 Hematopoietic Stem Cell Donor Selection in 2026: Evolving Perspectives and Current Challenges Room A Yunsuk Choi(University of Ulsan College of Medicine)
16:50~17:20 Flow Cytometric MRD for AML: Updates in 2026 Room B Jacqueline Cloos(Amsterdam UMC)
17:20~17:50 Targeting Residual Disease after Transplant: The Convergence of HCT and Engineered Cellular Therapies Room B Ran Reshef(Columbia University Irving Medical Center)
17:50~18:20 Clinical Experience with NGS-based Chimerism Analyses in HSCT Patients Room B Saeam Shin(Yonsei University College of Medicine)
16:50~17:20 Longitudinal Single-Cell Dissection of Venetoclax Resistance in Secondary AML Room C Semin Lee(UNIST)
17:20~17:50 Improving Post-transplant Immunological Outcome in AML by Modulating VISTA Room C Tae Kon Kim(Vanderbilt University Medical Center)
17:50~18:20 Immune Escape as a Mechanism of Post-transplant Relapse Room C Jaroslaw P. Maciejewski(Taussig Cancer Institute)